Surendra Kumar Saini

Surendra Kumar Saini

Auto-generated profile, based on publicly available information

Surendra Kumar Saini

Centre of Advanced Studies, Department of Chemistry, University of Rajasthan, Jaipur 302004, India

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SSSurendra Saini
Surendra Saini
PSPratibha Saini
Pratibha Saini
KKKrishan Kumar
Krishan Kumar
MSMukul Sethi
Mukul Sethi
PMPriyanka Meena
Priyanka Meena
VPVijay Parewa
Vijay Parewa

7 June 2002 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SASubramaniam Ananthan
Subramaniam Ananthan
SSSurendra K Saini
Surendra K Saini
RKRashmi Khare
Rashmi Khare
SCSarah D Clayton
Sarah D Clayton
CDChristina M Dersch
Christina M Dersch
RRRichard B Rothman
Richard B Rothman

6 October 2023 in E3S Web of Conferences
Verified
Conference Paper
Open access
PDF file
SSSurendra Kumar Saini
Surendra Kumar Saini
SKShaik Mohammed Khaja
Shaik Mohammed Khaja
Better toughness, abrasion resistance and machining characteristics make tool steel suitable material for dies and tools. Electrical discharge drilling is thermal energy based spark machining process. In this process metal removes from the work along circumference of hole to be cut is due to spark phenomena. In present study circular cutting on steel is performed with wire electric discharge machine using design of experiment approach. Four design variables pulse on & off time, wire feed and current have taken while material removal rate considered as quality parameters. Total nine experiments conducted on work material using orthogonal array. Taguchi technique is used to identify the significant process parameter on quality parameter.

1 May 2016 in Gaceta Mexicana de Oncología
Verified
Journal Article
Open access
SSSurendra Kumar Saini
Surendra Kumar Saini
SSShely Srivastava
Shely Srivastava
ADAwadhesh Kumar Dixit
Awadhesh Kumar Dixit
ResumenAntecedentesLa quimiorradiación es el tratamiento de referencia para el cáncer orofaríngeo e hipofaríngeo localmente avanzado, aunque solo unos cuantos pacientes sobreviven a largo plazo. Los novedosos agentes terapéuticos que actúan sobre los receptores EGFR han demostrado beneficios de supervivencia en el entorno paliativo y de radiosensibilización en estudios preclínicos. Comparamos la quimiorradiación concurrente basada en cisplatino frente a la quimiorradiación basada en cisplatino y gefitinib en pacientes con cáncer oro e hipofaríngeo locorregionalmente avanzado.MétodosPacientes de entre 18 y 70 años de edad con carcinoma epidermoide oro-hipofaríngeo localmente avanzado (estadios iii y iv, M0) fueron asignados aleatoriamente a radioterapia con cisplatino concurrente a 100mg/m2 los días 1, 23 y 43, o a radioterapia con cisplatino concurrente a la misma dosis más gefitinib 250mg al día iniciado 2 semanas antes de comenzar la radioterapia y hasta el final de la misma. Los criterios principal y secundario de valoración fueron la supervivencia libre de progresión y global, respectivamente.ResultadosDe un total de 67 pacientes asignados aleatoriamente, a 32 se les administró cisplatino con radiación (brazo i) y a 35 cisplatino más gefitinib con radiación (brazo ii). Las tasas de respuesta global (completa y parcial) fueron del 62 y el 71.42% en los brazos i y ii, respectivamente, sin que se registraran diferencias estadísticamente significativas (p=0.605). La mediana de supervivencia libre de progresión fue de 24 meses en el brazo i, en tanto que en el brazo ii fue de 35 meses (p=0.2877), proporción de riesgo (HR)=0.688; IC del 95%: 0.3346-1.4150). La mediana de supervivencia global fue de 31 meses en el brazo i y de 37 meses en el brazo ii (p=0.4344, HR=0.7542; IC del 95%: 0.3661-1.5539). La enfermedad proliferativa mostró una tendencia hacia la significación en términos de respuesta, aunque no pudo alcanzar el nivel de significación (p=0.086). No se encontró ninguna diferencia estadísticamente significativa en el perfil de toxicidad de los 2 brazos.ConclusiónLa combinación de gefitinib y cisplatino es bien tolerada en concurrencia con radiación, pero no presenta ningún efecto sorprendente sobre la tasa de respuesta, la supervivencia libre de progresión ni la supervivencia global, aunque se observaron resultados alentadores en la tasa de respuesta en la morfología proliferativa.AbstractBackgroundChemoradiation is standard treatment in locally advanced oropharyngeal and hypopharyngeal cancer but only few surviving for long term. Novel therapeutic agents targeting EGFR receptors demonstrated survival benefit in palliative setting and radiosensitization in preclinical studies. We compared cisplatin based concurrent chemoradiation with cisplatin and gefitinib based chemoradiation in patients with locoregionally advanced oro-hypo pharyngeal cancer.MethodsPatients of oro-hypo pharyngeal squamous cell carcinoma with age between 18 and 70 and with locally advanced (stage iii and iv, M0) were randomly assigned to receive either radiation with cisplatin 100mg/m2 on d1, 23 and 43 or radiation with cisplatin in same dose plus gefitinib 250mg daily started two week before commencing radiotherapy till the end of radiation treatment. Primary and secondary end points were progression free and overall survival, respectively.ResultsOut of total 67 patients randomized, 32 received cisplatin with radiation (arm i) and 35 received cisplatin plus gefitinib with radiation (arm ii). Overall response rates (complete and partial) were 62% and 71.42% in arm i and arm ii, respectively, with no statistically significant difference (P=.605). The median progression free survival was 24 months for arm i while it was 35 months for arm ii (P=0.2877, hazard ratio [HR]=0.688, 95% CI 0.3346-1.4150). The median overall survival was 31 months for arm i and 37 months for arm ii (P=.4344, HR=0.7542, 95% CI 0.3661-1.5539). Proliferative disease showed trend towards significance in terms of response but could not reach the level of significance (P=.086). No statisticallysignificant difference was found in toxicity profile of two arms.ConclusionGefitinib and cisplatin combination is well tolerated concurrently with radiation but does not have impressive effect on response rate, progression free survival and overall survival, but encouraging result was seen in response rate in proliferative morphology

5 April 2023 in Materials Today: Proceedings
Verified
Journal Article
Closed access
SSSurendra Kumar Saini
Surendra Kumar Saini
SKShaik Mohammed Khaja
Shaik Mohammed Khaja

23 September 2023 in Brachytherapy
Verified
Journal Article
Closed access
GNGopishankar Natanasabapathi
Gopishankar Natanasabapathi
DSDayanand Sharma
Dayanand Sharma
VSVellaiyan Subramani
Vellaiyan Subramani
SSSurendra Kumar Saini
Surendra Kumar Saini
DRDhanabalan Rajasekaran
Dhanabalan Rajasekaran